Elisabeth T Johansen1, Stine M Haustreis1, Ann S Mowinckel1, Lars M Ytrebø2. 1. Hospital Pharmacy of North Norway Trust, University Hospital of North Norway, Tromsø, Norway. 2. Critical Care Unit, University Hospital of North Norway and Institute of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Abstract
OBJECTIVES: An unacceptably high proportion of patients admitted to intensive care units (ICUs) develop drug-related problems (DRPs). DRPs might cause harm and increase costs and length of stay. The implementation of a clinical pharmacist service has been shown to detect a high number of DRPs and contributes effectively to solving these across different healthcare systems. However, this has not been prospectively studied in a mixed tertiary Norwegian ICU. METHODS: During a 12-month period from October 2012, a clinical pharmacist was dedicated to review medications 3 h daily (Monday to Friday). DRPs were reported at the ICU conference and included advice by the pharmacist for each case. All DRPs were categorised and the clinical impact was documented for later analysis. Drug-related questions from the staff were categorised and answered. RESULTS: 363 of 549 patients admitted to the ICU received medication reviews. 641 DRPs were detected in 194 of these patients (mean 1.8 DRPs per patient, range 0-25). Too high a dose, significant drug interactions and unnecessary or inappropriate drugs were among the most frequently detected DRPs. 87% of advice given by the pharmacist was accepted or taken into consideration. Typical questions from the nursing staff were related to drug preparation, generic equivalents and drug administration. Questions from doctors were most frequently related to drug dosage, efficiency and adverse effects. CONCLUSIONS: The addition of a dedicated clinical pharmacist to the ICU team improves the quality and safety of medication in a mixed Norwegian ICU.
OBJECTIVES: An unacceptably high proportion of patients admitted to intensive care units (ICUs) develop drug-related problems (DRPs). DRPs might cause harm and increase costs and length of stay. The implementation of a clinical pharmacist service has been shown to detect a high number of DRPs and contributes effectively to solving these across different healthcare systems. However, this has not been prospectively studied in a mixed tertiary Norwegian ICU. METHODS: During a 12-month period from October 2012, a clinical pharmacist was dedicated to review medications 3 h daily (Monday to Friday). DRPs were reported at the ICU conference and included advice by the pharmacist for each case. All DRPs were categorised and the clinical impact was documented for later analysis. Drug-related questions from the staff were categorised and answered. RESULTS: 363 of 549 patients admitted to the ICU received medication reviews. 641 DRPs were detected in 194 of these patients (mean 1.8 DRPs per patient, range 0-25). Too high a dose, significant drug interactions and unnecessary or inappropriate drugs were among the most frequently detected DRPs. 87% of advice given by the pharmacist was accepted or taken into consideration. Typical questions from the nursing staff were related to drug preparation, generic equivalents and drug administration. Questions from doctors were most frequently related to drug dosage, efficiency and adverse effects. CONCLUSIONS: The addition of a dedicated clinical pharmacist to the ICU team improves the quality and safety of medication in a mixed Norwegian ICU.
Entities:
Keywords:
DOCUMENTATION AND ARCHIVES; DRUG MANUFACTURING / PREPARATION / COMPOUNDING; DRUG PROCUREMENT; EDUCATION & TRAINING (see Medical Education & Training)
Authors: Rainu Kaushal; David W Bates; Erika L Abramson; Jane R Soukup; Donald A Goldmann Journal: Am J Health Syst Pharm Date: 2008-07-01 Impact factor: 2.637
Authors: Jeffrey M Rothschild; Christopher P Landrigan; John W Cronin; Rainu Kaushal; Steven W Lockley; Elisabeth Burdick; Peter H Stone; Craig M Lilly; Joel T Katz; Charles A Czeisler; David W Bates Journal: Crit Care Med Date: 2005-08 Impact factor: 7.598
Authors: Ulrika Gillespie; Anna Alassaad; Dan Henrohn; Hans Garmo; Margareta Hammarlund-Udenaes; Henrik Toss; Asa Kettis-Lindblad; Håkan Melhus; Claes Mörlin Journal: Arch Intern Med Date: 2009-05-11